Accessibility Menu
Helix BioMedix logo

Helix BioMedix(OTC) HXBM

Market Cap$1.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1995)-98%
5 Year-74%
1 Year+44%
1 Month+537%
$6.50
+8.33%
+0.50Today
Helix BioMedix last closing stock price
MetricPriceDate
Last closeUSD 6.502026-09-03
Helix BioMedix stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+271.43%USD 1.752026-08-24
1 month+537.25%USD 1.022026-07-27
3 month+263.13%USD 1.792026-05-29
Year to date+225%USD 2.002025-12-31
1 year+44.44%USD 4.502025-08-25
3 year-72.17%USD 23.362023-08-23
5 year-73.79%USD 24.802021-08-27
Since inception-98.42%USD 412.501995-07-26

Helix BioMedix Financials at a Glance

Market Cap

$1.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-0.08 (Low)

Price

$6.50

Volume

350

Open

$6.50

Previous Close

$6.50

Daily Range

$6.50 - $6.50

52-Week Range

$1.00 - $6.50

Estimated Earnings Date

Nov 9, 2012

HXBM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Helix BioMedix

Helix BioMedix, Inc. is a biopharmaceutical company focused on developing treatments for rare dermatological diseases, including Xeroderma Pigmentosum. Founded in 1988 and headquartered in Bothell, WA, the company aims to address significant unmet medical needs in the healthcare sector.

Products and Services
  • Innovative drug development for rare skin diseases
  • Research on peptide-based therapies
  • Collaboration with healthcare professionals for product efficacy
Growth Outlook
  • Market demand for dermatological treatments is increasing
  • Potential for partnerships with larger pharmaceutical companies
  • Focus on expanding product pipeline to address more conditions
Financial Highlights
  • Market capitalization stands at approximately $856 million
  • Current ratio of 12.16 indicates strong liquidity
  • Cash per share is reported at $5.64, providing financial stability
Helix BioMedix, Inc. operates in a niche market with significant growth potential, particularly in the treatment of rare dermatological conditions. The company's innovative approach to drug development, combined with a strong liquidity position, positions it well for future opportunities. The increasing market demand for specialized treatments and potential partnerships with larger firms could further enhance its growth trajectory. Investors may find the company's focus on expanding its product pipeline appealing, as it seeks to address additional medical needs in the dermatology space.
AI Generated • Sep 1, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Robin L. Carmichael

Website

www.helixbiomedix.com

Headquarters

Bothell, WA 98011, US

HXBM Financials

Key Financial Metrics (TTM)

Gross Margin

99.36%

Operating Margin

-73.81%

Net Income Margin

-68.32%

Return on Equity

-30.45%

Return on Capital

-38.72%

Return on Assets

-32.90%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

224.70K

Volume

350

Avg. Volume

98.938

Financials (TTM)

Gross Profit

$802.01K

Operating Income

-$595.81K

EBITDA

-$546.33K

Operating Cash Flow

-$601.07K

Capital Expenditure

-$3.00

Free Cash Flow

-$601.07K

Cash & ST Invst.

$1.27M

Total Debt

$0.00

Helix BioMedix Performance Analysis

Helix BioMedix annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,754,614-26.1%
20232023-12-31USD 997,726-43.1%
20242024-12-31USD 804,229-19.4%
20252025-12-31USD 807,1930.4%
Helix BioMedix annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -5.31-12.4%
20232023-12-31USD -4.70-11.4%
20242024-12-31USD -4.37-7.0%
20252025-12-31USD -2.45-43.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

$1.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SQZBSQZ Biotechnologies Company
$0.02+0.00%
PAIOFPaion AG
$0.07+0.00%
NSTMNovelStem International Corp.
$0.01+0.00%
ORGSOrgenesis Inc.
$0.03+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About HXBM

What is the current price of Helix BioMedix?

Helix BioMedix is trading at $6.50 per share.

What is the 52-week range for Helix BioMedix?

Over the past 52 weeks, Helix BioMedix has traded between $1.00 and $6.50.

How much debt does Helix BioMedix have?

As of the most recent reporting period, Helix BioMedix reported total debt of $0.00.

How much cash does Helix BioMedix have on hand?

Helix BioMedix reported $1.27M in cash and cash equivalents in its most recent financial results.

What is Helix BioMedix’s dividend yield?

Helix BioMedix does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services